Drugs / Moss-aGal
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02995993 | Nov 2016 → Oct 2017 | Fabry disease | Greenovation Biotech GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moss-aGal | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02995993 ↗ |
| Modality | Protein / enzyme biologic | “recombinant human alpha-galactosidase A produced in moss” NCT02995993 ↗ |
| Route | Intravenous | “as intravenous infusion” NCT02995993 ↗ |